Natural Killer Cell‐Based Immunotherapy in HCC
Immunology · 2026-08 · 178 (4) · 615-632
DOI: 10.1111/imm.70141 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunology, online erschienen am 28.04.2026. Verfasst von Linlin Che und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, Peopl…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy, Adoptive. Die Arbeit nennt 115 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai, National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) poses a formidable therapeutic challenge due to its high heterogeneity, frequent late‐stage diagnosis, and chemoresistance. Natural killer (NK) cells are essential for immune surveillance, yet their quantity and function become significantly compromised during HCC progression, thereby promoting tumour immune escape. This review systematically outlines current NK cell‐based immunotherapeutic strategies for HCC, including adoptive NK cell transfer, genetic engineering of NK cells, NK cell inhibitory receptor‐targeted therapies, reprogramming of the immunosuppressive HCC microenvironment, cytokine‐mediated enhancement of NK cell function, and traditional Chinese medicine‐augmented NK cell cytotoxicity. Representing a promising immunotherapeutic paradigm, NK cell‐based therapy is rapidly advancing from conventional cell infusion toward more precise modalities, including CAR‐NK cells and multifunctional antibody engagers. However, the efficacy of these approaches is frequently curtailed by the immunosuppressive tumour microenvironment and tumour heterogeneity. Given the multifactorial nature of NK cell dysfunction, we highlight that rationally designed combination strategies‐integrating genetic engineering, TME reprogramming, and checkpoint blockade‐represent the most viable path toward durable clinical responses in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
ORCID-Profile: Shiguo Zhu
Förderung
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
Zitieren
APA
Che, L., Xie, X., Yang, X., Zhu, S., & Zhou, Y. (2026). Natural Killer Cell‐Based Immunotherapy in HCC. Immunology, 178(4), 615-632. https://doi.org/10.1111/imm.70141
Vancouver
Che L, Xie X, Yang X, Zhu S, Zhou Y. Natural Killer Cell‐Based Immunotherapy in HCC. Immunology. 2026;178(4):615-632. doi:10.1111/imm.70141
BibTeX
@article{Che2026,
author = {Che, Linlin and Xie, Xueting and Yang, Xiaoyu and Zhu, Shiguo and Zhou, Yufu},
title = {Natural Killer Cell‐Based Immunotherapy in HCC},
journal = {Immunology},
year = {2026},
volume = {178},
number = {4},
pages = {615--632},
doi = {10.1111/imm.70141}
}
EUVIMED